4 Largecap FII Backed High Profit CAGR Stocks to Watch for Future Multibagger Potential: Titan, NTPC, Torrent Pharma and Apollo Hospitals
- November 5, 2026
- Posted by: Manan Bisht
- Category: Best Stocks
Titan Rs 4,754.40. NTPC Rs 321.95. Torrent Pharma Rs 4,738.50. Apollo Hospitals Rs 8,599.50. Market caps from Rs 1.29 lakh crore to Rs 4.31 lakh crore. Data as of 4 Nov 2026.
Quick Answer
Titan, NTPC, Torrent Pharma and Apollo Hospitals are the 4 picks in this FII backed high profit CAGR stocks watchlist, with market caps between Rs 1.29 lakh crore and Rs 4.31 lakh crore. Titan stands out for the highest return on equity at 32.31%, while NTPC offers the lowest PE of the group at 11.44. PE ratios run from 11.44 to 83.43, so compare each one with its industry PE before investing. All figures are as of 4 November 2026.
FII backed high profit CAGR stocks to watch for multibagger potential start with a simple filter: size, a clean financial record and earnings that keep growing. Titan, NTPC, Torrent Pharma and Apollo Hospitals meet that test, with market caps from Rs 1.29 lakh crore to Rs 4.31 lakh crore and Titan offering the highest return on equity at 32.31%. Each of these companies has a foreign institutional holding of at least 15 per cent and a four year profit CAGR of at least 15 per cent, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, and net profit rose in FY26 and in the latest quarter.
This list covers companies with a foreign institutional holding of at least 15 per cent and a four year profit CAGR of at least 15 per cent, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, rising profit in FY26 and the latest quarter, market capitalisation above Rs 1,00,000 crore, and complete, verifiable financials, ranked by market capitalisation. Each company has a market cap above Rs 1 lakh crore. Investors screening FII backed high profit CAGR stocks usually begin with size and balance sheet strength, and this list follows the same logic. All figures are as of 4 November 2026 and are drawn from NSE and BSE data and company filings.
Click Here – Get Free Investment Predictions
What Are FII Backed High Profit CAGR Stocks and Why Do They Attract Multibagger Interest?
FII backed high profit CAGR stocks are shares of large companies in which foreign institutions own at least fifteen per cent of the business and whose net profit has compounded at fifteen per cent or more a year over four years. The four here cover jewellery and watches, power generation, branded pharmaceuticals and hospitals.
Foreign funds apply strict checks before they buy, so a large stake in a company with a long record of profit growth shows that global money is backing earnings that compound. For FII backed high profit CAGR stocks, both FY26 and the latest quarter showed growth. Whichever way you read FII backed high profit CAGR stocks, the common thread is rising profit backed by complete financial data. A sensible way to study FII backed high profit CAGR stocks is to look at profit growth, returns and valuation side by side. Below, each of FII backed high profit CAGR stocks gets its own breakdown of growth, returns and valuation. Treat FII backed high profit CAGR stocks as a research list, since share prices and rankings change with every earnings season.
FII Backed High Profit CAGR Stocks at a Glance: Price, Market Cap, PE and ROE
Prices are closing prices as of 4 November 2026. NTPC has the lowest PE of the group at 11.44, while Titan posts the highest return on equity at 32.31%.
| Stock | CMP (Rs) | Market Cap (Rs Cr) | PE | Industry PE | ROE | Debt to Equity | 52-Week Range (Rs) |
|---|---|---|---|---|---|---|---|
| Titan Company | 4,754.40 | 4,31,307 | 74.88 | 46.75 | 32.31% | 0.93 | 3,506.50 to 5,186.70 |
| NTPC | 321.95 | 3,23,945 | 11.44 | 21.61 | 13.31% | 1.33 | 298.00 to 414.40 |
| Torrent Pharmaceuticals | 4,738.50 | 1,79,873 | 83.43 | 36.42 | 25.49% | 1.79 | 3,480.60 to 5,250.00 |
| Apollo Hospitals Enterprise | 8,599.50 | 1,29,030 | 59.40 | 60.75 | 20.48% | 0.90 | 6,696.50 to 9,070.50 |
Titan: 23.26% Profit CAGR Since FY22
Titan Company runs the jewellery (Tanishq), watches (Titan), eyewear and fragrances businesses. It reported FY26 revenue of Rs 88,136 crore, up 44.62% year on year, and net profit of Rs 5,073 crore, up 52.02%. Net profit has compounded at 23.26% a year since FY22, while revenue has grown 32.00% a year. Operating margin was 10.06% in FY26.
In the June 2026 quarter, revenue rose 29.31% to Rs 21,502 crore and net profit grew 62.88% to Rs 1,777 crore. The share price has gained 79.66% over five years and 27.64% over the past year. Domestic institutions raised their holding from 12.78% in June 2025 to 15.34% in June 2026. The stock trades at a PE of 74.88 against an industry PE of 46.75, with a return on equity of 32.31%.
NTPC: Five-Year Gain of 110.66%
NTPC is India’s largest power generation company and is growing its renewable energy portfolio. It reported FY26 revenue of Rs 1,89,798.56 crore and net profit of Rs 30,009.98 crore, up 48.19%. Net profit has compounded at 18.01% a year since FY22, while revenue has grown 8.89% a year. Operating margin was 32.45% in FY26.
The stock trades at a PE of 11.44 against an industry PE of 21.61, below the sector average, with a return on equity of 13.31%. The dividend yield is 2.70%. In the June 2026 quarter, revenue rose 6.94% to Rs 51,141.51 crore and net profit grew 12.90% to Rs 6,896.44 crore. The share price has gained 110.66% over five years. Domestic institutions raised their holding from 28.92% in June 2025 to 29.44% in June 2026.
Torrent Pharma: 28.79% Profit CAGR Since FY22
Torrent Pharmaceuticals makes branded medicines for chronic therapies such as cardiac, gastro-intestinal and central nervous system care in India and overseas. It reported FY26 revenue of Rs 13,886.15 crore, up 20.34% year on year, and net profit of Rs 2,138.18 crore, up 11.87%. Net profit has compounded at 28.79% a year since FY22, while revenue has grown 12.38% a year. Operating margin was 22.70% in FY26.
In the June 2026 quarter, revenue rose 56.29% to Rs 4,909 crore and net profit grew 3.28% to Rs 566 crore. The share price has gained 200.24% over five years and 32.19% over the past year. Domestic institutions raised their holding from 9.28% in September 2025 to 12.87% in July 2026. The stock trades at a PE of 83.43 against an industry PE of 36.42, with a return on equity of 25.49%.
Apollo Hospitals: Return on Equity of 20.48%
Apollo Hospitals Enterprise runs one of India’s largest hospital networks and also operates pharmacies and a digital health platform. It reported FY26 revenue of Rs 25,420.10 crore, up 15.58% year on year, and net profit of Rs 2,002.70 crore, up 33.06%. Net profit has compounded at 16.13% a year since FY22, while revenue has grown 14.59% a year. Operating margin was 15.80% in FY26.
The stock trades at a PE of 59.40 against an industry PE of 60.75, below the sector average, with a return on equity of 20.48%. In the June 2026 quarter, revenue rose 20.57% to Rs 7,092.30 crore and net profit grew 38.41% to Rs 610.40 crore. The share price has gained 86.54% over five years. Domestic institutions raised their holding from 21.12% in September 2025 to 22.07% in September 2026.
FII Backed High Profit CAGR Stocks: Financial Comparison on Growth and Margins
The table compares scale and growth across these FII backed high profit CAGR stocks. Latest quarter means the most recent reported quarter for each company, and only metrics that are positive for every company are shown.
| Stock | Revenue (Rs Cr) | Net Profit (Rs Cr) | 4-Year Revenue CAGR | 4-Year Net Profit CAGR | Latest Quarter Revenue Growth | Operating Margin (Latest Quarter) |
|---|---|---|---|---|---|---|
| Titan | 88,136 | 5,073 | 32.00% | 23.26% | 29.31% | 14.61% |
| NTPC | 1,89,798.56 | 30,009.98 | 8.89% | 18.01% | 6.94% | 35.04% |
| Torrent Pharma | 13,886.15 | 2,138.18 | 12.38% | 28.79% | 56.29% | 33.73% |
| Apollo Hospitals | 25,420.10 | 2,002.70 | 14.59% | 16.13% | 20.57% | 16.39% |
Check the Univest Screener for live data on these FII backed high profit CAGR stocks
Institutional Holding in Titan, NTPC, Torrent Pharma and Apollo Hospitals
Institutional holding shows who is backing these FII backed high profit CAGR stocks alongside the promoter. The table uses the latest reported quarter for each. Apollo Hospitals has the deepest institutional backing, with FII and DII together holding 65.25% as of September 2026. Domestic institutions increased their holding over the past year in Titan (from 12.78% to 15.34%), NTPC (from 28.92% to 29.44%), Torrent Pharma (from 9.28% to 12.87%) and Apollo Hospitals (from 21.12% to 22.07%).
| Stock | Promoter | FII | DII | Public | Quarter |
|---|---|---|---|---|---|
| Titan | 52.90% | 15.38% | 15.34% | 16.38% | June 2026 |
| NTPC | 51.10% | 16.30% | 29.44% | 3.15% | June 2026 |
| Torrent Pharma | 60.78% | 17.97% | 12.87% | 8.38% | July 2026 |
| Apollo Hospitals | 28.02% | 43.18% | 22.07% | 6.72% | September 2026 |
Risks to Weigh in FII Backed High Profit CAGR Stocks
Being careful with FII backed high profit CAGR stocks means looking at what can slow the story as well as what can speed it up. Four points matter most:
- Past growth may not repeat.
- Share prices can move sharply in either direction.
- Valuation: Torrent Pharma trades at a PE of 83.43 against an industry PE of 36.42, so earnings need to keep growing to support the price.
- Concentration: Holding all 4 names puts the allocation in one sector, so size each position to match your risk appetite.
How to Choose Between FII Backed High Profit CAGR Stocks
Picking from FII backed high profit CAGR stocks comes down to four checks, applied in order.
- Check balance sheet strength first, and prefer a debt-to-equity ratio below 1 for non-financial companies.
- Compare each PE with the industry PE (21.61 to 60.75) and ask whether the growth rate justifies any gap.
- Track net profit growth, the operating margin and the return on equity in every quarterly result.
- Stagger entries across quarters and review institutional holding every reporting season.
Download the Univest iOS App or Univest Android App to track Titan, NTPC, Torrent Pharma and Apollo Hospitals live prices.
Conclusion
Among FII backed high profit CAGR stocks, Titan stands out for the highest return on equity at 32.31%, NTPC for the lowest PE of the group at 11.44, Torrent Pharma for the fastest profit growth, 28.79% a year since FY22 and Apollo Hospitals for 15.58% revenue growth in FY26. Which one suits a portfolio depends on how much valuation risk it can carry, so staggering entries and reviewing each quarterly result is a sound habit. Investors comparing FII backed high profit CAGR stocks should rank them on growth, financial strength and the price paid, and anyone who wants personalised guidance can consult a SEBI-registered advisor before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on FII Backed High Profit CAGR Stocks to Watch
Which are the best FII backed high profit CAGR stocks to watch for multibagger potential?
Ans. Titan, NTPC, Torrent Pharma and Apollo Hospitals are the 4 names this list highlights, with market caps of Rs 4,31,307 crore, Rs 3,23,945 crore, Rs 1,79,873 crore and Rs 1,29,030 crore respectively. Titan is notable for the highest return on equity at 32.31%. NTPC stands out for the lowest PE of the group at 11.44. Torrent Pharma offers the fastest profit growth, 28.79% a year since FY22. Apollo Hospitals brings 15.58% revenue growth in FY26. These are watchlist names for FII backed high profit CAGR stocks, not recommendations, so match each one to your own risk profile and time horizon.
Is Titan a good stock for long-term investors?
Ans. Titan has a return on equity of 32.31%, a PE of 74.88 against an industry PE of 46.75 and a market cap of Rs 4,31,307 crore. Net profit has compounded at 23.26% a year since FY22, and FY26 revenue rose 44.62% while June 2026 quarter net profit grew 62.88%. Long-term returns in FII backed high profit CAGR stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.
Can Torrent Pharma become a multibagger from here?
Ans. Torrent Pharma has already gained 200.24% in five years, so another multi-fold move would need sustained earnings growth. A multibagger outcome in FII backed high profit CAGR stocks requires earnings to keep growing faster than the market for several years. Net profit has compounded at 28.79% a year since FY22, and FY26 revenue rose 20.34%. At a PE of 83.43 against an industry PE of 36.42, valuation should be checked against that growth before investing.
What is the market cap of Titan, NTPC, Torrent Pharma and Apollo Hospitals?
Ans. As of 4 November 2026, Titan has a market cap of Rs 4,31,307 crore, NTPC has a market cap of Rs 3,23,945 crore, Torrent Pharma has a market cap of Rs 1,79,873 crore and Apollo Hospitals has a market cap of Rs 1,29,030 crore. All of them qualify as largecaps. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on FII backed high profit CAGR stocks.
What are the risks of investing in FII backed high profit CAGR stocks?
Ans. The main risks are market swings, slower growth than expected and valuations that already reflect good news. Companies with strong balance sheets and steady earnings handle these better. Torrent Pharma trades at a PE of 83.43 against an industry PE of 36.42, so earnings growth needs to hold up.
Why is Torrent Pharma trading at a PE of 83.43?
Ans. Torrent Pharma’s PE of 83.43 compares with an industry PE of 36.42. The market is paying a premium for a return on equity of 25.49%, profit growth of 28.79% a year since FY22 and FY26 revenue growth of 20.34%, which also means the stock is more sensitive if growth slows. Investors in FII backed high profit CAGR stocks who are comfortable with higher valuation risk may prefer to stagger purchases instead of investing in one go.
How much do institutions hold in Titan, NTPC, Torrent Pharma and Apollo Hospitals?
Ans. As of the latest reported quarter, FII and DII together hold 30.72% of Titan (15.38% and 15.34%), 45.74% of NTPC (16.30% and 29.44%), 30.84% of Torrent Pharma (17.97% and 12.87%) and 65.25% of Apollo Hospitals (43.18% and 22.07%). Rising institutional holding is a useful signal in FII backed high profit CAGR stocks, though it should be read with earnings trends rather than on its own.
